Cymbiotika, a leading wellness and supplement brand committed to transforming health through innovative, science-backed formulations, has completed a $30 million debt financing round. The funding was led by RevTek Capital.
This partnership with RevTek Capital allows Cymbiotika to strengthen its balance sheet. It provides the necessary working capital to support key initiatives, including expansion into retail, entering the Canadian market, and enhancing infrastructure and automation. These efforts will drive exponential revenue and EBITDA growth in 2025 and beyond.
Cymbiotika picked RevTek Capital due to their proven ability to offer flexible financing solutions tailored to high-growth companies. And this funding will not only accelerate the company’s product innovation pipeline but also fortify Cymbiotika’s operational efficiency and support continued investment in delivering premium, high-quality supplements to its rapidly expanding customer base.
The funding will also provide Cymbiotika with the resources to optimize its supply chain and scale its digital and omnichannel marketing efforts, ensuring the company is well-positioned to meet both its immediate and long-term growth goals.
KEY QUOTES:
“The successful completion of this financing round signifies the strength of our brand, the value of our products, and our immense potential in the market. RevTek Capital made the entire process incredibly smooth and easy for us. Their team’s deep knowledge and expertise were evident every step of the way, and they provided invaluable guidance in structuring this financing. This partnership allows us to further scale our operations, enter new markets, and drive long-term sustainable growth. We’re excited for the road ahead and our continued mission to empower individuals to take control of their health.”
– Shahab Elmi, CEO and Co-Founder of Cymbiotika
“Cymbiotika is a remarkable company that has grown rapidly by staying true to its mission of delivering premium wellness products. At RevTek, we are proud to partner with forward-thinking companies like Cymbiotika that are making a meaningful impact on people’s lives. We look forward to supporting their continued success and growth.”
– Scott Peters, CEO and Founder of RevTek Capital
